
May 16 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB RECEIVES EUROPEAN COMMISSION APPROVAL FOR PERIOPERATIVE REGIMEN OF NEOADJUVANT OPDIVO® (NIVOLUMAB) AND CHEMOTHERAPY FOLLOWED BY ADJUVANT OPDIVO FOR RESECTABLE, HIGH-RISK NON-SMALL CELL LUNG CANCER WITH PD-L1 EXPRESSION ≥1%